The last common male ancestor of all humans is far older than previously thought, scientists have found. When the family of Albert Perry, an African-American living in South Carolina, submitted his DNA to commercial genealogy company Family Tree DNA, it was discovered that his Y chromosome was so distinct that his male lineage likely separated from all others around 338,000 years ago.
Biopharma giant Abbvie has announced the acquisition of Allergan for $63 billion in cash and stock. Abbvie said the deal would be “transformational” for both companies, allowing Abbvie to diversify its business while focusing on scientific research and the company’s pipeline.
University of Connecticut scientists have found that both severe epilepsy and breathing irregularities leading to sudden death are linked to the same gene mutation.
From 1 July, international scientists looking to use Chinese genetic material and data must have at least on Chinese collaborator working with them, according to new regulations. This follows a trend as individuals and organisations realise the value of their genetic data.
Consumer genomics company Ancestry has launched the new upgrade to its AncestryDNA experience, Ancestry Communities. Contrary to many commercial DNA sites, Communities promises to specify UK users’ genetic ancestry to a county level.
Research by James Scargill of the University of California suggests that 2D universes could sustain life. His work states that a universe with two spatial dimensions and one temporal one could also work, overcoming critical problems with the issue of gravity and the necessity for a set degree of complexity.
The CMA has announced that Illumina’s $1.2 billion acquisition of Pac Bio is potentially anti-competitive, delaying the expected conclusion of the deal until fourth quarter 2019. The CMA said the deal could remove Illumina’s biggest competitor, leaving limited alternatives available for customers.
BIO 2019 – An Interview with Irene Rombel, Senior Director and Head of Strategic Analysis at Janssen
With the recent conclusion of the Biotechnology Innovation Organization’s BIO 2019 event, we thought we’d talk to some of the fascinating individuals who were present to showcase their innovative ideas or technologies. Irene Rombel, Senior Director, Head of Strategic Analysis – External Innovation, Discovery, Product Development & Supply, at Janssen Research & Development, spoke at BIO 2019 about gene therapy and the next generation of biotherapeutics. We spoke to her about her thoughts on the gene therapy field, and the future for companies in that space.
eGenesis has announced that it is now testing pig organs on primates to see if they safe for human use. If successful, this practice could solve the current shortage of human organs for transplantation. The company has declared that the pig organs are the most highly engineered ever created by surgeons.
A joint US-China study has engineered macaque monkeys to express a mutation linked to autism and other human neurodevelopmental disorders. The monkey showed certain behavioural traits similar to humans with the same condition.
Russian biologist Denis Rebrikov has announced his intentions to produce further gene-edited babies, ignoring the scientific consensus that this should not be done until an ethical framework is constructed to regulate the science involved. Rebrikov’s plans could occur before the end of the year if he receives approval in time.
As part of the Next Generation Children project at Addenbrooke’s Hospital and Cambridge University, all seriously ill children in England with unexplained disorders will be able to have their genomes analysed from 2020. The project should mean quicker diagnoses for families in the future.
Dr. Eric Kmiec, Director of the Gene Editing Institute at Christiana Care Health System, spoke at BIO 2019 about meeting unmet medical needs with gene editing. We spoke to him about his work at Christiana Care Health System and CRISPR’s role in promoting better social equality in life science.
A new experimental version of CRISPR could help fix genes rather than disable them using transposons, or “jumping genes”. This could help move the current “find and delete” purpose of CRISPR to the more useful “find and replace” one.
The US government has ended medical research funding for scientists using foetal tissue, and cancelled a multi million-dollar contract for a laboratory at the University of California at San Francisco, which required the material to test new HIV therapies. According to a White House spokesperson, the decision was taken by President Trump himself.